buy generic valtrex without a prescription where can i buy xenical online in the uk levofloxacin salep mata neurontin 600 mg en espanol what is xenical 120 mg used for levitra original 20 mg viagra vs levitra vs cialis better viagra para mujeres en gotas pomegranate juice natural viagra cialis vs staxyn propranolol over the counter canada ordering clomid canada effexor 150 mg paxil 5 mg side effects priligy order online prix cialis 10 mg viagra 50mg rezeptfrei viagra rotterdam erfahrung viagra bestellen cialis bestellen where to get amoxicillin without a prescription uk ventolin tablet 2 mg 100 tb ciprofloxacin hydrochloride tablets i p 500 mg ventolin evohaler order online
le flagyl truvada le monde levoxacin e augmentin

Lymphoseek designated fast track status in head and neck cancer

Wed, Dec 11, 2013

Oral Cancer News

Author: press release

Navidea announced that the FDA has granted Fast Track designation to Lymphoseek (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer. Lymphoseek Injection is a novel, receptor-targeted, small-molecule radiopharmaceutical designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer.

Lymposeek Injection was evaluated in a prospective, open-label, multicenter, within-patient study (NEO3-06). It was designed to identify sentinel lymph nodes (SLNs) and determine the false negative rate (FNR) associated with Lymphoseek-identified SLNs relative to the pathological status of non-SLNs in head and neck and intraoral squamous cell carcinoma. The primary endpoint for the NEO3-06 trial was based on the number of subjects with pathology-positive lymph nodes following a multiple level lymph node dissection. A minimum of 38 subjects whose lymph nodes contained pathology-confirmed disease was required. Thirty nine subjects out of over 80 subjects enrolled were determined to have pathology-positive lymph nodes.

Navidea intends to file the supplemental New Drug Application (sNDA) for Lymphoseek before the end of 2013. Lymphoseek is already approved for use in lymphatic mapping to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma.

Print Friendly
Be Sociable, Share!
, , ,

Leave a Reply

You must be logged in to post a comment.